Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053085 · ClinicalTrials.gov registry record · Phase 2
A Study of Surgery and Radiotherapy in People With Breast Cancer
A Phase 2 study of Metastatic Breast Cancer and HER2-positive Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
- 7
- Study locations
NCT07053085: Recruiting Phase 2 study of Metastatic Breast Cancer and HER2-positive Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07053085 is a Phase 2 study of Metastatic Breast Cancer and HER2-positive Breast Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 162 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (21% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07053085, a Phase 2 study of Metastatic Breast Cancer and HER2-positive Breast Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will also study the side effects of the study treatment.
Primary Outcome
with PFS defined as the time of randomization to the date of clinical or radiographic disease progression or death (by any cause in the absence of progression).
Conditions Studied
Interventions
- RADIATION Radiotherapy
- PROCEDURE Lumpectomy or mastectomy
- DRUG Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activites) - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2029-09-17 |
| Phase | Phase 2 |
What NCT07053085 shows while recruiting
NCT07053085 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (21% lower).
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Radiotherapy is the first listed.
NCT07053085 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT07053085 about?
NCT07053085 is a clinical study titled "A Study of Surgery and Radiotherapy in People With Breast Cancer". The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will ...
What is the current status of trial NCT07053085?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2025-09-17. Estimated completion is 2029-09-17.
What conditions does trial NCT07053085 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer.
What interventions are being tested in trial NCT07053085?
The interventions under investigation include: Radiotherapy (RADIATION), Lumpectomy or mastectomy (PROCEDURE), Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs (DRUG).
Who is sponsoring clinical trial NCT07053085?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07053085 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07053085's enrollment target sits among peer trials
162 41st of 139 higher than 99 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
-
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI